ログイン
ランキング
お知らせ
ログイン
文献詳細
文献概要
特集 循環器診療 薬のギモン—エキスパートに学ぶ薬物治療のテクニック Ⅲ．虚血性心疾患・SHD診療でのギモン
PCI後の抗血小板薬は，やめるタイミングはいつ？
著者： 北原秀喜1 小林欣夫1
所属機関： 1千葉大学大学院医学研究院循環器内科学
ページ範囲：P.72 - P.79
文献購入ページに移動Point
・第2世代以降の薬剤溶出性ステント（DES）では，抗血小板薬2剤併用療法（DAPT）は6カ月，もしくは症例によっては3カ月で中止可能と考えられる．
・心血管イベントのハイリスク症例においては，出血リスクを鑑みつつ長期DAPTも検討すべきである．
・抗血栓薬3剤併用はできるだけ短期間とし，抗凝固薬は直接経口抗凝固薬（DOAC）の低用量を，抗血小板薬はクロピドグレルを中心としたレジメンを考慮する．
・第2世代以降の薬剤溶出性ステント（DES）では，抗血小板薬2剤併用療法（DAPT）は6カ月，もしくは症例によっては3カ月で中止可能と考えられる．
・心血管イベントのハイリスク症例においては，出血リスクを鑑みつつ長期DAPTも検討すべきである．
・抗血栓薬3剤併用はできるだけ短期間とし，抗凝固薬は直接経口抗凝固薬（DOAC）の低用量を，抗血小板薬はクロピドグレルを中心としたレジメンを考慮する．
参考文献
1) Steg PG, Bhatt DL, Wilson PW et al:One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297:1197-1206, 2007
2) Mehta RH, Parsons L, Peterson ED;National Registry of Myocardial Infarction Investigators:Comparison of bleeding and in-hospital mortality in Asian-Americans versus Caucasian-Americans with ST-elevation myocardial infarction receiving reperfusion therapy. Am J Cardiol 109:925-931, 2012
3) Authors/Task Force members;Windecker S, Kolh P, Alfonso F, et al:2014 ESC/EACTS Guidelines on myocardial revascularization:The Task Force on Myocardial Revascularization of the European Society of Cardiology（ESC）and the European Association for Cardio-Thoracic Surgery（EACTS）Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions（EAPCI）. Eur Heart J 35:2541-2619, 2014
4) Levine GN, Bates ER, Bittl JA, et al:2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines:An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation 134:e123-155, 2016
5) Natsuaki M, Morimoto T, Yamamoto E, et al:One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation:ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent（STOPDAPT）trial. Cardiovasc Interv Ther 31:196-209, 2016
6) Takahara M, Kitahara H, Nishi T, et al:Very early tissue coverage after drug-eluting stent implantation:an optical coherence tomography study. Int J Cardiovasc Imaging 33:25-30, 2017
7) Finn AV, Joner M, Nakazawa G, et al:Pathological correlates of late drug-eluting stent thrombosis:strut coverage as a marker of endothelialization. Circulation 115:2435-2441, 2007
8) Mauri L, Kereiakes DJ, Yeh RW, et al:Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371:2155-2166, 2014
9) Bonaca MP, Bhatt DL, Cohen M, et al:Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372:1791-1800, 2015
10) Wohrle J, Zadura M, Mobius-Winkler S, et al:SeQuentPlease World Wide Registry:clinical results of SeQuent please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study. J Am Coll Cardiol 60:1733-1738, 2012
11) Kimura T, Kozuma K, Tanabe K, et al:A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease:ABSORB Japan. Eur Heart J 36:3332-3342, 2015
12) Raber L, Brugaletta S, Yamaji K, et al:Very Late Scaffold Thrombosis:Intracoronary Imaging and Histopathological and Spectroscopic Findings. J Am Coll Cardiol 66:1901-1914, 2015
13) Lip GY, Windecker S, Huber K, et al:Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions:a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association（EHRA）, European Association of Percutaneous Cardiovascular Interventions（EAPCI）and European Association of Acute Cardiac Care（ACCA）endorsed by the Heart Rhythm Society（HRS）and Asia-Pacific Heart Rhythm Society（APHRS）. Eur Heart J 35:3155-3179, 2014
14) Kirchhof P, Benussi S, Kotecha D, et al:2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893-2962, 2016
15) Ruff CT, Giugliano RP, Braunwald E, et al:Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation:a meta-analysis of randomised trials. Lancet 383:955-962, 2014
16) Dewilde WJ, Oirbans T, Verheugt FW, et al:Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention:an open-label, randomised, controlled trial. Lancet 381:1107-1115, 2013
17) Oldgren J, Wallentin L, Alexander JH, et al:New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome:a systematic review and meta-analysis. Eur Heart J 34:1670-1680, 2013
18) Daida H, Miyauchi K, Ogawa H, et al:Management and two-year long-term clinical outcome of acute coronary syndrome in Japan:prevention of atherothrombotic incidents following ischemic coronary attack（PACIFIC）registry. Circ J 77:934-943, 2013
19) Gibson CM, Mehran R, Bode C, et al:Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 375:2423-2434, 2016
20) Lamberts M, Gislason GH, Lip GY, et al:Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant:a nationwide cohort study. Circulation 129:1577-1585, 2014
掲載誌情報
